Able Wealth Management »

4d Molecular Therapeutics In shares owned by Able Wealth Management

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by Able Wealth Management from 13F filings

Historical chart of Able Wealth Management investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by Able Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by Able Wealth Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $181 9 20.22

More positions owned by Able Wealth Management

iShares Short Treasury Bond ETF Etf (SHV)
iShares MSCI ACWI ETF Etf (ACWI)
iShares Core S&P 500 ETF Etf (IVV)
iShares Edge MSCI Min Vol USA ETF Etf (USMV)
iShares Core S&P U.S. Value ETF Etf (IUSV)
Fidelity Enhanced Large Cap Core Etf Stock (FELC)
iShares Core S&P U.S. Growth ETF Etf (IUSG)
JPMorgan U.S. Quality Factor ETF Etf (JQUA)
Invesco S&P 100 Equal Weight ETF Etf (EQWL)
iShares Russell 1000 Growth ETF Etf (IWF)
iShares Core S&P Total U.S. Stock Market ETF Etf (ITOT)
Apple Stock (AAPL)
iShares S&P 500 Value ETF Etf (IVE)
Mastercard Incorporated Stock (MA)
Pacer US Cash Cows 100 ETF Etf (COWZ)

View all positions for Able Wealth Management

Top funds holding 4d Molecular Therapeutics In

Viking Global Investors
RA Capital Management
BVF
VR Adviser
Henderson Group
Vanguard Group
Arrowpoint Asset Management
Casdin Capital
Goldman Sachs Group
Dimensional Fund Advisors
Deutsche Bank Aktiengesellschaft
Eagle Health Investments
Assenagon Asset Management
Jpmorgan Chase & Co
Point72 Asset Management

View all funds holding 4d Molecular Therapeutics In